Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

New AI tool revolutionizes drug discovery for rare diseases

There are more than 7,000 rare and undiagnosed diseases globally.

25 Sep 2024

Neuroactive drugs show promising anti-glioblastoma effects in preclinical trials

Study explores the potential to repurpose neuroactive drugs, originally approved for neurological disorders, for the treatment of glioblastoma. Vortioxetine, an antidepressant, showed promising anti-glioblastoma activity, significantly reducing tumor size in preclinical trials.

24 Sep 2024

ACBI3 molecule offers new hope for targeting KRAS mutations in cancer

KRAS is the most mutated gene in cancer with mutations occurring in 17%–25% of all cancers, affecting millions of patients worldwide.

23 Sep 2024

Urgent call for long-term investment in antibiotic research

Antibiotic resistance is a global public health threat. Modern health systems rely on antibiotics to prevent and treat infections, and the need for new drugs is urgent.

23 Sep 2024

Broken String Biosciences appoints Laurence Reid and Brad Crutchfield to its Board of Directors

Broken String Biosciences enhances its leadership team with Laurence Reid and Brad Crutchfield, aiming to revolutionize cell and gene therapy development.

From Broken String Biosciences 23 Sep 2024

New biomarkers offer hope for early detection and prevention of Alzheimer's

The failure to diagnose Alzheimer's disease, the most common form of dementia in the elderly, at an early stage of molecular pathology is considered a major reason why treatments fail in clinical trials. Previous research to molecularly diagnose Alzheimer's disease yielded "A/T/N" central biomarkers based on the measurements of proteins, β-amyloid ("A") and tau ("T"), and "N" encompassing neurodegeneration. A/T/N can be measured in brain tissue, by in vivo brain imaging techniques, and by analysis of cerebrospinal fluid and plasma.

18 Sep 2024

PlaqueTec and RxCelerate collaborate on early phase drug discovery for coronary artery disease

PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), and RxCelerate, a leading international out-sourced drug discovery and development service provider, today announced the successful completion of a collaboration to assess small molecules identified from an initial cheminformatics drug screen in a bespoke cell-based assay developed by RxCelerate on one of PlaqueTec’s targets discovered in pilot studies.

18 Sep 2024

Early specificity testing crucial for antibody drug safety

Integral Molecular, a leader in antibody discovery and characterization, has published new research in the journal mAbs, revealing that as many as one-third of antibody-based drugs exhibit nonspecific binding to unintended targets.

18 Sep 2024

Ohio State's novel DHODH inhibitor enters first human trials

A new therapeutic agent discovered and developed at The Ohio State University will soon be used for cancer treatment at the patient's bedside as part of a clinical trial.

17 Sep 2024

The Key Role of iPSC-Derived Microglia in Research and Drug Discovery

Dr. Tilman explains the functions of iPSC-derived microglia and their relevance to conditions like Alzheimer’s.

From Axol Bioscience Ltd 17 Sep 2024

Newcells Biotech launches high-content and high-throughput imaging suite to advance pre-clinical drug development programmes

Newcells Biotech (“Newcells”), a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes, today announced the launch of its imaging suite and advanced lung Fibroblast-to-Myofibroblast Transition (FMT) assay.

From Newcells Biotech 17 Sep 2024

ESMO Congress 2024 to unveil future-focused cancer treatments

The ESMO Congress 2024 will hold a press conference to introduce and discuss the "Eyes to the Future" Presidential Symposium 3, that will be presenting prominent approaches that have the potential to become increasingly effective and influential components of cancer treatment in the (near) future.

16 Sep 2024

ISM2196: A promising AI-developed WRN inhibitor for advanced metastatic cancers

Insilico Medicine("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced the nomination of ISM2196, an AI-driven, potential best-in-class small molecule WRN inhibitor targeting advanced metastatic microsatellite instability (MSI) cancers guided by synthetic lethality strategy.

13 Sep 2024

QB3-led team awarded $12 million to explore autism origins with advanced models

A QB3-led team uniting researchers from the University of California campuses at Berkeley, San Francisco, and Santa Cruz was awarded a $12 million grant from the California Institute for Regenerative Medicine (CIRM) to investigate the origins of autism using sophisticated cellular models called "neural organoids."

12 Sep 2024

New algorithm unveils key genetic mutations across multiple cancers

A computer algorithm can efficiently find genetic mutations that work together to drive cancer as well as other important genetic clues that researchers might someday use to develop new treatments for a variety of cancers.

11 Sep 2024

Ropirio Therapeutics secures exclusive license for novel lymphatic system activators

The Wyss Institute at Harvard University announced today that Ropirio Therapeutics, Inc. (Ropirio) has secured a worldwide, exclusive license from Harvard's Office of Technology Development (OTD) and Boston University (BU)'s Technology Development office for novel molecules that activate the lymphatic system - a first in the pharma industry.

11 Sep 2024